Grant Williams is an Oncology physician.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
2000 6th Ave S
Birmingham, AL 352332110
Telephone
205-934-9999Registry record last updated 14 Apr 2016.
Industry payments
66 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Takeda Pharmaceuticals U.S.A., Inc.Program year20256 payments
- Novartis Pharmaceuticals CorporationProgram year202510 payments
- AstraZeneca Pharmaceuticals LPProgram year202510 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
26.7%Phenothiazine15.2%Prochlorperazine Maleate100%Part D≥43 patientsOpioid Agonist11.5%Oxycodone-Acetaminophen41%Oxycodone Hcl35%Morphine Sulfate Er25%Part D<11 patientsMetabolism & gastrointestinal
24.8%Serotonin-3 Receptor Antagonist19%Ondansetron Hcl100%Part D≥53 patientsCorticosteroid5.9%Prednisone100%Part D<11 patientsCancer & immunology
15.5%Aromatase Inhibitor7.7%Letrozole100%Part D<11 patientsCytochrome P450 17A1 Inhibitor4.7%Abiraterone Acetate100%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2018–2022 per NIH RePORTER. The latest:
- Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults with Colorectal Cancer: The M&M Study
University of Alabama at Birmingham
FY2022$206,920K08CA234225 - Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults with Colorectal Cancer: The M&M Study
University of Alabama at Birmingham
FY2021$205,981K08CA234225 - Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults with Colorectal Cancer: The M&M Study
University of Alabama at Birmingham
FY2020$206,920K08CA234225
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Freddie Bray
Centre National de la Recherche Scientifique
Jacques Ferlay
Centre international de recherche sur le cancer
Hermann Brenner
German Cancer Research Center
Isabelle Soerjomataram
Centre international de recherche sur le cancer
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”